Another influential voice takes Bristol-Myers’ top execs to task as they scramble to shore up the big Celgene buyout
Brad Loncar is not a big fan of the executive teams at either Bristol-Myers Squibb or Celgene.
Today, as Bristol-Myers scrambled to win investors’ backing, the Loncar Cancer Immunotherapy ETF outlined why it would line up with the growing — though still marginal — opposition that has gathered around the mega-buyout since Wellington, with 8% of Bristol’s shares, said it would be voting against the deal. Loncar joins the activists at Starboard Value who have planted their flag with the rebellion.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.